2008 BioPacific Conference Agenda

8:00 – 9:00am Registration and Networking
9:00 – 9:05am Welcome Remarks
Leping Li, Ph.D., President-elect of CABS
9:05 – 9:10am President’s Remarks
Naibo Yang, Ph.D., President of CABS
  Plenary Session, Chaired by Leping Li
9:10 – 9:20am Introductory Remarks, Bill Rutter, Ph.D., CEO of Synergenics
9:20 – 10.00am Regis Kelly, Ph.D., Director of California Institute of Quantitative Biosciences (QB3)
10:00 – 10.40am Jim Wells, Ph.D., Harry W. and Diana Hind Distinguished, Professor in Pharmaceutical Sciences at UCSF
“Drug Discovery at the Challenging Interface”
10:40 – 11:00am Coffee break & vendor show
  Innovative Research and Therapeutic Modality, Chaired by Jing-Shan Hu, Ph.D.
11:00 – 11:30am Alan Sacks, Ph.D. M.D., Vice President, RNA Therapeutics, Merck Research Laboratories
“RNAi-Based Therapeutics: Promise and Challenges”
11:30 – 12:00am Mark Kay, Ph.D. M.D., Dennis Farrey Family Professor at Stanford University
12:00 – 12:15pm Presentation by Beijing Alliance of BioBox Outsourcing (ABO)
12:15 – 1:30pm Lunch
1:00 – 1:30pm Slide show: 10 years of SAPA-west & C
  Innovative Research and Therapeutic Modality, Chaired by Shichang Miao, Ph.D.
1:30 – 2:00pm Didier Stainier, Ph.D., Professor of Biochemistry and Biophysics at UCSF
“Endodermal organ development and regeneration in zebrafish”
2:00 – 2:30pm Mark Gallop, Ph.D. Co-Founder & Sr. Vice President of Research, Xenoport
“Harnessing Nutrient Transport Mechanisms to Optimize Drug Absorption and Disposition in vivo”
3:00 – 3:30pm Coffee break & vendor show
3:40 – 4:00pm Michael Zielenziger, Consultant, Monitor Group
“China’s Future in Life Sciences: New Drivers of Innovation”
  New Business Opportunities, Chaired by Tao Huang, Ph.D. J.D., & Liming Yang, Ph.D.
3:30 – 4:00pm William Keller, Vice President, Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Co., Ltd
4:00 – 4:20pm Jing-Shan Hu, Ph.D., Director of Licensing and External Research, (mainland China, Hong Kong, Taiwan) Merck & Co.
“Partnership: a Model for Success”
4:20 – 4:50pm Tom Duley, J.D., Of Counsel, Morgan Lewis & Bockius LLP
“Harnessing the Value of IP: Critical Factors in Biotech Transactions”
4:50 – 6:20pm Satellite meeting in a separate room with ABO of Beijing
4:50 – 7:00pm Break, dinner, performance shows (Chaired by Min Bao)
  Special Evening Session on the Future of Biotech and Pharmaceutical Business In China
Chaired by Naibo Yang and Leping Li
7:00 – 7:20pm Marietta Wu, M.D., Ph.D., MBA, Vice President, Burrill Co.
7:20 – 7:40pm Tony Zhang, Ph.D. Managing Director, Site Head, Eli Lily Global Research China
“From FIPCo to FIPNet, transformation of Eli Lilly’s Global R&D”
7:40 – 8:00pm Xiaochuan Wang, Ph.D., CEO of Sundia Meditech
“Historic Opportunities”
8:00 – 8:50pm Panelists also include:
Cheng Liu, Ph.D., CEO of Eureka Therapeutics,
Tom Duley, J.D., Jing-Shan Hu, Ph.D.
Yajun Xu, Ph.D., Vice President of Biology, Chempartners